EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The 2024 APLAR Consensus on the Management of Lupus Nephritis

Chi Chiu Mok iD, Ho So iD, Laniyati Hamijoyo iD, Nuntana Kasitanon iD, Der Yuan Chen iD, Sang Cheol Bae iD, Meng Tao Li, Sandra Navarra iD, Desmond Yat Hin Yap iD, Yoshiya Tanaka iD

International Journal of Rheumatic Diseases · 2025-01 · 28 (1)

DOI: 10.1111/1756-185x.70021 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Rheumatic Diseases, online erschienen am 02.01.2025. Verfasst von Chi Chiu Mok und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Tuen Mun Hospital, Hong Kong, SAR, China. Hauptthemen laut MEDLINE: Lupus Nephritis, Immunosuppressive Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 227 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The APLAR has published a set of recommendations on the management of systemic lupus erythematosus (SLE) in 2021. The current consensus paper supplements and updates specifically the treatment of lupus nephritis (LN) according to two rounds of Delphi exercise from members of the APLAR SLE special interest group, invited nephrologists, histopathologists, and lupus nephritis patients. For initial treatment of LN, we recommend a combination of glucocorticoids (GCs) with cyclophosphamide (CYC), mycophenolate mofetil (MMF), or the calcineurin inhibitors (CNIs) as first‐line options. An upfront combination of immunosuppressive drugs and the biological agents may be considered in patients at significant risk of disease progression and renal function deterioration. Switching or “add‐on” among different immunosuppressive agents, including biological agents, may be considered for refractory disease. Subsequent/maintenance therapy of LN should continue for at least 3 years to reduce the risk of renal flares. Lower dose MMF and azathioprine are options, but MMF maintenance should follow induction by the same drug. Prednisolone or equivalent should be maintained at a dose of 5 mg/day or less. The APLAR consensus for the management of LN includes recommendations for adjunctive therapies, monitoring and treatment of LN‐related co‐morbidities, and renal replacement therapies. It is hoped that this consensus paper can provide an evidence‐based and pragmatic approach to the management of LN, taking into account the evidence level of therapies in Asian patients, cost‐effectiveness, and differences in health care resources and reimbursement policies in the Asia‐Pacific region.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus NephritisImmunosuppressive AgentsHumansDrug Therapy, CombinationTreatment OutcomeDelphi TechniqueGlucocorticoidsRheumatology

Stichwörter der Autor:innen

APLARconsensusglomerulonephritisguidelinelupusnephritis

Substanzen

Immunosuppressive AgentsGlucocorticoids

Autor:innen und Institutionen

  • Department of Medicine, Tuen Mun Hospital, Hong Kong, SAR, China.
  • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, SAR, China.
  • Rheumatology Division, Department of Internal Medicine, Padjadjaran University, Bandung, Indonesia.
  • Division of Rheumatology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Rheumatology and Immunology Centre, China Medical University Hospital, Taichung, Taiwan.
  • Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Hanyang University Institute for Rheumatology Research and Hanyang Institute of Bioscience and Biotechnology, Seoul, South Korea.

ORCID-Profile: Chi Chiu Mok, Ho So, Laniyati Hamijoyo, Nuntana Kasitanon, Der Yuan Chen, Sang Cheol Bae, Sandra Navarra, Desmond Yat Hin Yap, Yoshiya Tanaka

Zitieren

APA

Mok, C. C., So, H., Hamijoyo, L., Kasitanon, N., Chen, Y., Bae, S. C., Li, M. T., Navarra, S., Yap, D. Y. H., & Tanaka, Y. (2025). The 2024 APLAR Consensus on the Management of Lupus Nephritis. International Journal of Rheumatic Diseases, 28(1). https://doi.org/10.1111/1756-185x.70021

Vancouver

Mok CC, So H, Hamijoyo L, Kasitanon N, Chen Y, Bae SC, et al. The 2024 APLAR Consensus on the Management of Lupus Nephritis. International Journal of Rheumatic Diseases. 2025;28(1). doi:10.1111/1756-185x.70021

BibTeX
@article{Mok2025,
  author = {Mok, Chi Chiu and So, Ho and Hamijoyo, Laniyati and Kasitanon, Nuntana and Chen, Der Yuan and Bae, Sang Cheol and Li, Meng Tao and Navarra, Sandra and Yap, Desmond Yat Hin and Tanaka, Yoshiya},
  title = {The 2024 APLAR Consensus on the Management of Lupus Nephritis},
  journal = {International Journal of Rheumatic Diseases},
  year = {2025},
  volume = {28},
  number = {1},
  doi = {10.1111/1756-185x.70021}
}
Kostenlos starten →